Disc Medicine, Inc. has reported a substantial sale of its common stock by Atlas Venture Fund X, L.P., amounting to approximately $819,291.76. This transaction, filed on October 19, 2026, is significant as it reflects the ongoing activities and strategies within the pharmaceutical preparations sector.
The sale involved 14,414 shares of common stock, which were sold through Merrill Lynch as the broker. This move indicates a strategic decision by Atlas Venture Fund X, L.P., a shareholder in Disc Medicine, to capitalize on its investment in the company.
Background
Disc Medicine, Inc. operates in the pharmaceutical preparations industry, classified under SIC code 2834. The company is publicly traded on the Nasdaq under the ticker symbol IRON. It has been actively engaging with investors, as evidenced by its recent filings, including multiple Form 144 submissions in October 2026 alone.
What the Filing Says
The filing states, "The approximate sale date is 10/19/2026," and notes that the securities were acquired through a private placement back in May 2020. The filing also confirms that there were no securities sold in the past three months prior to this transaction.
Impact
This transaction may affect various stakeholders, notably investors and analysts monitoring Disc Medicine's financial health and market strategies. The sale of shares indicates a potential shift in investment strategy by Atlas Venture Fund, which could influence other investors' perceptions of the company's future prospects.
What's Next
The filing does not specify what happens next regarding further sales or investments by Atlas Venture Fund X, L.P., nor does it outline any upcoming corporate actions by Disc Medicine.
Source: SEC Filing Accession Number 0001628280-26-066325